PELP1 and neoplasm: Future efforts should focus on improving the pharmacokinetic properties and tumor selectivity of PELP1 inhibitors, such as SMIP34, and exploring combination strategies with endocrine therapy, CDK inhibitors, DNA damage response, or immunotherapy to overcome resistance mechanisms.